Evolution of the Liquid Biopsy in Metastatic Prostate Cancer.
Publication/Presentation Date
10-1-2019
Abstract
We reviewed the literature for the biologic, prognostic, and predictive significance of circulating prostate cancer tumor cells (CTCs), and circulating tumor DNA in the blood of metastatic castration resistant prostate cancer patients. CTCs demonstrate robust prognostic value independent of PSA in predicting overall survival. The CTC androgen receptor variant receptor 7 phenotype predicts resistance to androgen receptor synthesis inhibitors and sensitivity to taxane based chemotherapy in metastatic castration resistant prostate cancer patients who are candidates for second line therapy. Research is rapidly pivoting toward circulating tumor DNA analysis because the approach is sensitive, prognostic, cost effective, and it can elucidate mechanisms of systemic therapy.
Volume
132
First Page
1
Last Page
9
ISSN
1527-9995
Published In/Presented At
Moreno, J. G., & Gomella, L. G. (2019). Evolution of the Liquid Biopsy in Metastatic Prostate Cancer. Urology, 132, 1–9. https://doi.org/10.1016/j.urology.2019.06.006
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
31207303
Department(s)
Administration and Leadership
Document Type
Article